HC Wainwright Has Negative Opinion of ORKA FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for Oruka Therapeutics to a loss of $2.69 per share from a loss of $2.54, while maintaining a Buy rating. Its FY2026 estimate is more negative than the analyst consensus loss of $2.42 per share.
• Oruka reported a quarterly loss of $0.63 per share, missing analysts’ expected loss of $0.60. HC Wainwright also forecast a FY2027 loss of $3.22 per share.
• Analyst sentiment is broadly positive: MarketBeat’s consensus rating is “Moderate Buy,” with a $133 average price target from 11 analysts. Investors are also watching for ORKA-001’s 52-week data, expected in December, and a planned Phase 3 trial start in 2027.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - HC Wainwright decreased their FY2026 earnings per share estimates for Oruka Therapeutics in a report released on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.69) per share for the year, down from their prior estimate of ($2.54). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q4 2026 earnings at ($0.74) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.85) EPS and FY2027 earnings at ($3.22) EPS.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03).

ORKA has been the subject of a number of other research reports. Piper Sandler reissued an "overweight" rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. BTIG Research restated a "buy" rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday. Wedbush reaffirmed an "outperform" rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Finally, Guggenheim reiterated a "buy" rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research report on Monday, October 26th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $133.00.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $107.17 on Thursday. The firm has a 50 day moving average of $89.12 and a 200 day moving average of $71.65. Oruka Therapeutics has a twelve month low of $25.23 and a twelve month high of $115.51.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 9,999 shares of the firm's stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the completion of the sale, the senior vice president owned 14,219 shares of the company's stock, valued at approximately $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $74.81, for a total value of $523,670.00. Following the sale, the insider owned 31,771 shares in the company, valued at $2,376,788.51. The trade was a 18.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 169,950 shares of company stock worth $15,426,080. 23.49% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently added to or reduced their stakes in ORKA. Nykredit A S acquired a new stake in Oruka Therapeutics during the second quarter worth about $29,000. GAMMA Investing LLC grew its position in shares of Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company's stock valued at $31,000 after purchasing an additional 250 shares during the period. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $91,000. Sterling Capital Management LLC raised its stake in Oruka Therapeutics by 839.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company's stock valued at $138,000 after purchasing an additional 1,485 shares during the last quarter. Finally, Natural Investments LLC purchased a new position in shares of Oruka Therapeutics in the second quarter worth about $202,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Top Oruka Therapeutics Stories

These are some of the ORKA stories that stood out recently:

• Positive Sentiment: BTIG Research reiterated its Buy rating and set a $151 price target. Oruka Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: UBS also initiated or reiterated a Buy rating, adding another favorable analyst view. Oruka Therapeutics Receives a Buy from UBS
• Neutral Sentiment: Investors are looking ahead to 52-week data for ORKA-001 expected in December, with a Phase 3 trial start planned for 2027. The data could be an important pipeline catalyst. Oruka Expects ORKA-001 52-Week Data in December

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.